Post-thrombotic syndrome prevention on patients after COVID-19

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/3972

Title:	Post-thrombotic syndrome prevention on patients after COVID-19
Authors:	Akmal Irnazarov, Uktamkhon Asrarov, Jakhongir Matmuradov
Keywords:	Arterial and venous thromboses are most frequent complications after COVID-19. According to JAMA Open Network, on 2/3 patients after coronavirus infection developed arterial and venous thromboses. Rupin Aria discovers thrombotic events on 70% after coronavirus infection despite taking antiplatelet therapy.
Issue Date:	12-Sep-2022
Publisher:	Turkey
Abstract:	There were 64 male gender patients from December 2020 until July 202l in Multidisciplinary clinic of Tashkent Medical Academy with acute iliofemoral venous thrombosis, which were divided into 2 groups. All patients had had coronavirus infection 2-2.5 months before hospitalization. Main group included 29 patients, whom peroral anticoagulant had been carried out in the next scheme: Rivaroxaban 40 mg qDay l st week, then Rivaroxaban 30 mg q Day for 2 weeks and Rivaroxaban 20 mg qDay for 3 months. Control group had taken standard scheme of therapy.
URI:	http://repository.tma.uz/xmlui/handle/1/3972
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
6.pdf	Post-thrombotic syndrome prevention on patients after COVID-19	46.1 kB	Adobe PDF	View/Open

DSpace JSPUI